|
TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
ANTICOAGULANT EFFECT IS REDUCED
|
MAY INCREASE DROWSINESS EFFECT
|
PHENOTHIAZINES HAVE SOME ALPHA-ADRENERGIC BLOCKING ACTIVITY & MAY REDUCE THE PRESSOR EFFECTS AND DURATION OF ACTION OF PHENYLEPHERINE / SYMPATHOMIMETICS
|
INCREASED SEDATIVE EFFECT
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|
TRICYCLIC ANTIDEPRESSANTS METABOLISM IS REDUCED BY THE DRUG LEADING TO INCREASED SERUM LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND POSSIBLE TOXICITY
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS TRICYCLIC ANTIDEPRESSANTS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
TRICYCLIC ANTIDEPRESSANTS METABOLISM IS REDUCED BY THE DRUG LEADING TO INCREASED SERUM LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND POSSIBLE TOXICITY
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS TRICYCLIC ANTIDEPRESSANTS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
TRICYCLIC ANTIDEPRESSANTS METABOLISM IS REDUCED BY THE DRUG LEADING TO INCREASED SERUM LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND POSSIBLE TOXICITY
|
INCREASES QT PROLONGATION WHICH COULD CAUSE ARRHYTHMIAS
|
INCREASES QT PROLONGATION WHICH COULD CAUSE ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
MAY INCREASE DROWSINESS EFFECT
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|
PHENOTHIAZINES CAN INHIBIT GONADOTROPHIN SECRETION LEADING TO LOSS OF LEUPROLIDE ACTION
|
CHLORPROMAZINE WHEN USED CONCOMITANTLY RESULTS IN INCREASED PLASMA LEVELS OF BOTH THE DRUGS
|
LEVODOPA EFFECT IS REDUCED BY THE DRUG
|
LINOLEIC OR LINOLENIC ACID CAN PRECIPITATE SYMPTOMS OF UNDIAGNOSED TEMPORAL LOBE EPILEPSY WITH THOSE TAKING EPILEPTOGENIC DRUGS, PARTICULARLY PHENOTHIAZINES
|
LINOLEIC OR LINOLENIC ACID CAN PRECIPITATE SYMPTOMS OF UNDIAGNOSED TEMPORAL LOBE EPILEPSY WITH THOSE TAKING EPILEPTOGENIC DRUGS, PARTICULARLY PHENOTHIAZINES
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
INCREASED INCIDENCE OF SIDE EFFECTS ON CO-ADMINISTRATION
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
LINOLEIC OR LINOLENIC ACID CAN PRECIPITATE SYMPTOMS OF UNDIAGNOSED TEMPORAL LOBE EPILEPSY WITH THOSE TAKING EPILEPTOGENIC DRUGS, PARTICULARLY PHENOTHIAZINES
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|
PHENOTHIAZINES LIKE CHLORPROMAZINE REVERSES ANTIHYPERTENSIVE EFFECTS OF THE DRUG
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|
PHENOTHIAZINES, TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
PHENOTHIAZINES, TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
PHENOTHIAZINES, TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
PHENOTHIAZINES, TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
PHENOTHIAZINES, TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
PHENOTHIAZINES, TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY INCREASE DROWSINESS EFFECT
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS TRICYCLIC ANTIDEPRESSANTS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
TRICYCLIC ANTIDEPRESSANTS METABOLISM IS REDUCED BY THE DRUG LEADING TO INCREASED SERUM LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND POSSIBLE TOXICITY
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
PHENOTHIAZINES, TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|
PHENOTHIAZINES, TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|
PHENOTHIAZINES, TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
PHENOTHIAZINES, TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
PHENOTHIAZINES, TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
PHENOTHIAZINES, TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
PHENOTHIAZINES, TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
PHENOTHIAZINES HAVE SOME ALPHA-ADRENERGIC BLOCKING ACTIVITY & MAY REDUCE THE PRESSOR EFFECTS AND DURATION OF ACTION OF PHENYLEPHERINE / SYMPATHOMIMETICS
|
MAY INCREASE DROWSINESS EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
CHLORPROMAZINE WHEN USED CONCOMITANTLY RESULTS IN INCREASED PLASMA LEVELS OF BOTH THE DRUGS
|
MAY INCREASE DROWSINESS EFFECT
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
MAY INCREASE DROWSINESS EFFECT
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
MAY POTENTIATE ORTHOSTATIC HYPOTENSION
|
MAY INCREASE DROWSINESS EFFECT
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
MAY INCREASE DROWSINESS EFFECT
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|
CO-ADMINISTRATION OF PROSTAGLANDIN SYNTHASE INHIBITING DRUGS, SUCH AS INDOMETHACIN, MAY DECREASE THE HYPOTENSIVE EFFECTS OF BETA-BLOCKERS
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|
TRICYCLIC ANTIDEPRESSANTS METABOLISM IS REDUCED BY THE DRUG LEADING TO INCREASED SERUM LEVELS OF TRICYCLIC ANTIDEPRESSANTS AND POSSIBLE TOXICITY
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
PHENOTHIAZINES LIKE CHLORPROMAZINE REVERSES ANTIHYPERTENSIVE EFFECTS OF THE DRUG
|